In 2017, Bloomage Biotech (SH: 699363), a Chinese leader in hyaluronic acid, acquired the French counterpart Revitacare for a total of 14.275 million euros. This acquisition provided Bloomage Biotech with access to Revitacare’s French research talent, customer resources, distribution networks, and the Cytocare product line. It marked Bloomage Biotech’s first overseas acquisition.
The Cytocare line is familiar to many beauty enthusiasts. In 2018, Cytocare 715 C line, a functional skincare product, entered the Chinese market. Revitacare’s revenue grew nearly fivefold, …
